Wayne State University

Sciclone Pharmaceuticals, Inc.

Alpha 1 Biomedicals

US Government as Represented by the Secretary of the Army

Milton G Mutchnick

Paul B Chretien

Frederick E Weller

A method for the treatment of viral induced hepatitis B in mammals, particularly humans, by injecting a thymosin is described. The method is particularly effective in the treatment of chronic hepatitis B using bovine calf thymosin fraction 5 which contains thymosin alpha.sub.1 or bovine calf or synthetic thymosin alpha.sub.1.

Method for the treatment of hepatitis

A method of treating Hepatitis C by administering an immune system-potentiating dose of at least one Thymosin or system-potentiating Thymosin fragment to a mammal infected with Hepatitis C virus, which Hepatitis C infection in the mammal is non-responsive to treatment with interferon alone.

Method of treating hepatitis C in non-responders to interferon treatment

Compositions and methods of use for treating hepatitis C virus-infected mammals are disclosed. The compositions include one or more thymosins alone or in combination with one or more interferons. Methods of treatment include use of thymosins alone, or together, or sequentially with interferon.

Composition and method of treating hepatitis C

Method and composition for treatment of patients having decompensated

A method and composition for treating autoimmune hepatitis in a patient utilizes an immunomodulatory amount of T.alpha..sub.1 and an anti-inflammatory amount of a corticosteroid.

Method for treatment of autoimmune hepatitis

A micro-enzyme described immunosorbent assay (microELISA) method is described for detecting small amounts of thymosin alpha.sub.1 in a solution such as serum. The method uses a known amount of an antibody to the thymosin alpha.sub.1 which is reacted with the thymosin alpha.sub.1 in solution to form a first complex. The solution with the first complex and unreacted antibody is then contacted with thymosin alpha.sub.1 bound to a solid phase which quantitatively forms a second complex with the unreacted antibody. The amount of the second complex is determined and correlated with the amount of thymosin alpha.sub.1 of the solution. Thymosin alpha.sub.1 is an important hormone the presence or absence of which is significant clinically.

Growing community of inventors

West Bloomfield, MI, United States of America

Milton G Mutchnick